Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform
August 23, 2021 08:00 ET
|
Orgenesis Inc.
Goal to accelerate development, QC testing and manufacturing of Orgenesis’ cell and gene therapy platform New assays being developed to potentially enhance the potency of cell and gene therapies for...
Orgenesis Second Quarter 2021 Revenue Increases Over Six-Fold to $10.5 Million Compared to Second Quarter 2020 Reflecting Continued Progress of POCare Platform
August 05, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Schedules Second Quarter 2021 Business Update Conference Call
August 03, 2021 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Achieves Multiple Ranpirnase Development Milestones
July 06, 2021 07:00 ET
|
Orgenesis Inc.
FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on schedule Licensing partner, Okogen, Inc., presented positive interim phase 2 clinical trial...
Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair
June 10, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd
June 01, 2021 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform
May 07, 2021 07:00 ET
|
Orgenesis Inc.
Achieves operating profit for the first quarter of 2021 Cash and cash equivalents of $41.8 million as of March 31, 2021 ...
FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection
May 06, 2021 07:30 ET
|
Orgenesis Inc.
IDE approval provides important validation of clinical development plans for the Icellator2 GERMANTOWN, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the...
Orgenesis Schedules First Quarter 2021 Business Update Conference Call
May 05, 2021 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of Care Cell and Gene Therapy Center
March 29, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...